Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
China Resources Pharmaceutical Group Ltd. (3320.HK)
Wan Chai, HK, HK
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.08% | -1.27% | -11.05% | +2.64% | -2.51% | +4.94% | -9.32% | -37.57% | -16.16% | -48.17% | -48.17% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 6 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | -1 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+9.4% ★ Q4'25: +14.3% (vs Q4'23)
-
EPS growth Medical - Pharmaceuticals: +20.2%+28.6% ★ Q4'25: +84.2% (vs Q4'23)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%+4.7% Q4'25: +11.1% (vs Q4'23)
-
EBIT margin Medical - Pharmaceuticals: +6.8%+4.7% Q4'25: +3.9% (vs Q4'23)
-
ROIC Medical - Pharmaceuticals: +6.1%+6.5% ★ Q4'25: +11.6% (vs Q4'23)
-
Share dilution Medical - Pharmaceuticals: +0.0%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×5.92× Q4'25: 3.30× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 11 Rev. Ana. 9 EPS Ana. |
Dec 2027 11 Rev. Ana. 10 EPS Ana. |
Dec 2028 4 Rev. Ana. 4 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
156.71B
est: 152.90B (+2.5%)
|
172.53B
est: 167.24B (+3.2%)
|
189.69B
est: 190.12B (-0.2%)
|
204.45B
est: 205.75B (-0.6%)
|
200.42B
est: 199.67B (+0.4%)
|
236.81B
est: 227.87B (+3.9%)
|
254.11B
est: 254.83B (-0.3%)
|
270.40B
est: 250.48B (+8.0%)
|
274.18B
est: 272.22B (+0.7%)
|
300.01B
est: 295.52B (+1.5%)
|
330.14B
326.13B – 339.67B
+11.7% YoY
|
347.91B
336.41B – 362.20B
+5.4% YoY
|
362.49B
354.20B – 375.22B
+4.2% YoY
|
| EBITDA |
9.95B
est: 8.78B (+13.4%)
|
10.74B
est: 4.90B (+119.2%)
|
13.66B
est: 5.01B (+172.7%)
|
12.58B
est: 4.62B (+172.2%)
|
12.47B
est: 3.68B (+238.5%)
|
11.95B
est: 4.05B (+194.8%)
|
15.47B
est: 4.28B (+261.3%)
|
15.43B
est: 16.34B (-5.6%)
|
15.45B
est: 18.03B (-14.3%)
|
17.70B
est: 19.28B (-8.2%)
|
21.53B
21.27B – 22.16B
+11.7% YoY
|
22.69B
21.94B – 23.63B
+5.4% YoY
|
23.64B
23.10B – 24.48B
+4.2% YoY
|
| EBIT |
8.81B
est: 7.00B (+25.9%)
|
9.04B
est: 11.00B (-17.9%)
|
12.04B
est: 11.62B (+3.6%)
|
10.21B
est: 13.09B (-22.0%)
|
10.02B
est: 10.39B (-3.5%)
|
9.12B
est: 11.43B (-20.2%)
|
12.32B
est: 12.08B (+2.0%)
|
12.27B
est: 13.59B (-9.8%)
|
12.75B
est: 15.01B (-15.0%)
|
14.08B
est: 16.04B (-12.2%)
|
17.92B
17.70B – 18.43B
+11.7% YoY
|
18.88B
18.26B – 19.66B
+5.4% YoY
|
19.67B
19.22B – 20.36B
+4.2% YoY
|
| Net Income |
2.82B
est: 3.29B (-14.3%)
|
3.48B
est: 3.17B (+9.9%)
|
4.04B
est: 3.79B (+6.4%)
|
3.29B
est: 4.33B (-24.0%)
|
2.78B
est: 3.34B (-16.9%)
|
3.08B
est: 3.68B (-16.2%)
|
3.50B
est: 4.16B (-15.9%)
|
3.85B
est: 3.78B (+2.0%)
|
3.57B
est: 4.25B (-16.1%)
|
4.50B
est: 4.04B (+11.4%)
|
4.97B
4.71B – 5.23B
+22.9% YoY
|
5.29B
4.66B – 5.92B
+6.5% YoY
|
5.90B
5.43B – 6.36B
+11.4% YoY
|
| SGA |
14.83B
est: 15.53B (-4.5%)
|
18.12B
est: 16.79B (+7.9%)
|
23.13B
est: 19.82B (+16.7%)
|
24.41B
est: 25.27B (-3.4%)
|
22.51B
est: 25.30B (-11.0%)
|
24.44B
est: 27.83B (-12.2%)
|
21.97B
est: 29.42B (-25.3%)
|
27.79B
est: 25.24B (+10.1%)
|
28.26B
est: 27.86B (+1.4%)
|
32.48B
est: 29.78B (+9.1%)
|
33.26B
32.86B – 34.22B
+11.7% YoY
|
35.05B
33.90B – 36.50B
+5.4% YoY
|
36.52B
35.69B – 37.81B
+4.2% YoY
|
| EPS |
0.57
est: 0.52 (+8.8%)
|
0.55
est: 0.53 (+3.4%)
|
0.64
est: 0.66 (-2.7%)
|
0.52
est: 0.61 (-15.0%)
|
0.52
est: 0.55 (-4.7%)
|
0.60
est: 0.60 (-0.2%)
|
0.66
est: 0.67 (-1.9%)
|
0.68
est: 0.60 (+13.1%)
|
0.56
est: 0.67 (-16.5%)
|
0.72
est: 0.62 (+16.9%)
|
0.80
0.75 – 0.83
+29.7% YoY
|
0.87
0.74 – 0.94
+8.7% YoY
|
0.91
0.86 – 1.01
+5.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-28 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-27 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-26 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-22 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-21 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-20 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-19 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-18 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-15 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-14 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-13 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-12 | A- | 4/5 | 4/5 | 4/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-11 | A- | 4/5 | 4/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 3/5 | 3/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 3/5 | 3/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 3/5 | 3/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-05 | B+ | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | B+ | 3/5 | 3/5 | 3/5 | 3/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A- | 4/5 | 3/5 | 3/5 | 4/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-22 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-21 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-20 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-17 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | B+ | 3/5 | 3/5 | 3/5 | 4/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | First Trust Emerging Markets Equity Select ETF RNEM | 1.45% | 244.0K | 0.76% |
| 2 | iShares MSCI China Small-Cap ETF ECNS | 0.71% | 463.8K | 0.59% |
| 3 | VictoryShares Emerging Markets Value Momentum ETF UEVM | 0.67% | 1.62M | 0.53% |
| 4 | First Trust Emerging Markets AlphaDEX UCITS ETF FEMU.L | 0.35% | 51.2K | 0.80% |
| 5 | Vident International Equity Strategy ETF VIDI | 0.32% | 1.25M | 0.61% |
| 6 | First Trust RiverFront Dynamic Emerging Markets ETF RFEM | 0.21% | 164.8K | 0.99% |
| 7 | JPMorgan International Value ETF JIVE | 0.15% | 4.93M | 0.55% |
| 8 | Avantis Emerging Markets Small Cap Equity ETF AVEE | 0.12% | 140.2K | 0.42% |
| 9 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.10% | 70.6K | 0.74% |
| 10 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.08% | 473.0K | 0.55% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Xiaosong Bai | Executive Chairman of the Board | 3M | male |
| Changan Liu | Executive Director | 1M | male |
| Jie Cheng | President & Executive Director | 1M | male |
| Madam Rong Deng | Chief Financial Officer | 911.0K | — |
| Ting Guo | Chairman of China Resources Pharmaceutical Commercial Group | — | male |
| Wing Yi Wan | Company Secretary | — | female |
| Yanwei Huang | Chief Financial Officer of CR Jiangzhong | — | — |
| Guo Junyu | VP and Chief Strategy Officer of CR Business Group | — | — |
| Ju Liu | Board Secretary & Vice President of China Res Double-Crane | — | — |
| Ren Hui | President of Boya Bio-pharmaceutical | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 3320.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
